In this study, restricting our protocol to individuals under the age of 70 years would decrease both the number of tumours screened and the number of tumours requiring MLH1 promoter methylation analysis by 26% and 28%, respectively, while still identifying all individuals found to have a germline PV. Here, MLH1 is linked to neoplasm.